Board of Directors

Martin Driscoll

Chairman, President and Chief Executive Officer

Marty joined Spring Bank in 2015 as President, Chief Executive Officer and Director. Previously, he served as CEO of Asmacure Ltée, a venture-backed, clinical-stage biopharmaceutical company which he joined in late 2010. Asmacure Ltée was acquired by a privately-held Canadian life sciences company in July 2015. Prior to Asmacure, Marty was the CEO and a director of Javelin Pharmaceuticals, Inc., a publicly-traded developer of acute care pain products, from March 2008 until July 2010 when he engineered the merger of Javelin with Hospira, Inc. He also served in various senior management roles at Schering-Plough Corporation, ViroPharma, Inc. and Reliant Pharmaceuticals, Inc. In 2007, Marty co-founded Pear Tree Pharmaceuticals, Inc., a privately-held developer of women’s healthcare products. He has been involved with or led the commercialization of several important therapies,the direct negotiation of numerous licensing and M&A transactions, multiple private and public capital fundraising efforts and the successful submission of major product regulatory filings. Marty also served as a director on the boards of four private and public biopharmaceutical development companies andcurrently serves on the board of AsmacureLtéeand Metastat, Inc., a molecular diagnostics company based in Boston. Marty holds a BSc in communications from the University of Texas at Austin. He is a trustee of the Barn for the Poorest of the Poor, a non-profit food pantry based in New Jersey.


David Arkowitz


David joined our board of directors in 2014. He brings more than 20 years of finance and operations leadership experience in thehealthcare, life sciences and biotechnology industries. David currently serves as Chief Operating Officer and Chief Financial Officer of Visterra, Inc. Prior to joining Visterra, he was at MascomaCorporation, a bioconversion company, where he served as Chief Financial Officer and General Manager. Previously, David was Chief Financial Officer and Chief Business Officer of AMAG Pharmaceuticals, a commercial stage public biopharmaceutical company, where he hada broad range of operational and general management responsibilities. Prior to his tenure at AMAG, he served as Chief Financial Officer and Treasurer of IdenixPharmaceuticals, Inc. where he assisted with the company’s initial public offering. Earlier in his career, he spent more than13years at Merck & Co. Inc., including as Vice President and Controller of the U.S. Human Health division and as Controller of the Global Research and Development division. David served on the board of directors of Aegerion Pharmaceuticals, Inc. and ImpactRx.


R. P. “Kris” Iyer, PhD

Co-Founder, Chief Scientific Officer

Kris is an innovator in the fields of nucleic acid chemistry, bioorganic chemistry and pharmaceutical sciences. He was co-founder and VP of Discovery of OrigenixTechnologies, Inc. from 1998 to 2002. There he directed a team of 30 scientists in chemistry and biology and was instrumentalin advancing several programs from discovery to clinical development. From 1993 to 1998, Kris was a Senior Scientist and Associate Director of theDiscovery Group at Hybridon, Inc. (now IderaPharmaceuticals, Inc.). Previously, Kris was a Professor of Medicinal Chemistry at the University of Bombay, a Visiting Scientist at the University of Texas, M.D. Anderson Cancer Center and a Visiting Scientist at the Center for Biologics Evaluation and ResearchatFDA/NIH. Kris received his BS (Hons) in chemistry, BS and MS degrees in Medicinal and Pharmaceutical Chemistry from the University of Bombay. He received his PhD degree in Pharmaceutical Sciences from the University of the Pacific, Stockton, California and carried out postdoctoral work at the OakRidge National Laboratory and at the Johns Hopkins University. He is an author of over 100 scientific papers and several books on organic synthesis and is an inventor of more than 100 patents and patent applications. In 2004, Kris was elected as a Fellow of Royal Society of Chemistry, UK and in 2008 he was elected as a Fellow of International Society of Physical Sciences. In 2004, he was awarded the M. L. Khorana Memorial Award by the Indian Pharmaceutical Association and in 2003 elected as the UICT Diamond Jubilee Distinguished Fellow in Pharmaceutical Sciences. Kris has served on the Scientific Advisory Board of TopigenPharmaceuticals, Inc. and currently serves on the National Institutes of Health (NIH) review panel for grants and contracts.


Jonathan Bates


Jonathan joined our board of directors in 2008. He is a Managing Director of Altexa, Inc., a company that develops international and domestic businesses across industry sectors from energy to international trade. Jonathan is also the founder of HB Financial Services, Inc. He has worked with many private and public companies, consulting on a broad range of services including financial and organizational planning, capital structuresand formations, equity and bridge financing, and arranging debt financing. He has held directorship positions in both public and private companies and has worked extensively with investment banks, public relations firms and broker-dealers to help these companies achieve their expansion goals.


Kurt M. Eichler


Kurt joined our board of directors in 2015. In 1979, Kurt began his career at Merrill Lynch Hubbard Inc. in the Real Estate Debtand Equity Finance Group. In 1982, he joined The LinproCompany (now LCOR, Inc.) as Director of Commercial and Industrial Operations for the suburban Philadelphia area. In 1983, he became Operating Partner in the Center City Philadelphia Office. Kurt was Executive Vice President and Principal of LCOR in charge of operations of the metropolitan New York region. Based in New York City, Kurt served on LCOR’s Executive Committee. Kurt has served on several boards over the last decade including DARA BioSciences, Inc. (now MidatechPharma US), MiMedxGroup, Inc. and Maia Yogurt. Kurt holds a BS from the University of Wyoming.


Dr. Todd Brady


Dr. Brady joined our Board of Directors in July of 2016 and brings extensive experience in the areas of biopharmaceutical development and leadership. He currently serves as Chief Executive Officer, President and Director of Aldeyra Therapeutics (Nasdaq:ALDX), a developer of drugs for the treatment of inflammation and inborn errors of metabolism.
Dr. Brady was appointed President and Chief Executive Officer of Aldeyra Therapeutics in 2012, having been a member of the Board of Directors since 2005. Dr. Brady also served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, in 2013. Prior to joining the firm as a Principal in 2004 Dr. Brady held senior leadership positions at Aderis Pharmaceuticals, Inc., Xanthus Life Sciences, Inc., and Phenome Sciences. Dr. Brady also serves on the Board of Directors of Oncobiologics, Inc. and Evoke Pharma, Inc., both of which are publicly traded biotechnology companies, as well as a number of privately-held biotechnology companies.